Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin‐Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations

Aberrations of the cell cycle are pervasive in cancer, and selective cell cycle inhibition of cancer cells is a target of choice for a number of novel cancer therapeutics. Cyclin‐dependent kinases (CDKs) are key regulatory enzymes that control cell cycle transitions and the commitment to cell divisi...

Descripción completa

Detalles Bibliográficos
Autores principales: Spring, Laura M., Zangardi, Mark L., Moy, Beverly, Bardia, Aditya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AlphaMed Press 2017
Materias:
Breast Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5599204/
https://www.ncbi.nlm.nih.gov/pubmed/28706010
http://dx.doi.org/10.1634/theoncologist.2017-0142

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5599204/
https://www.ncbi.nlm.nih.gov/pubmed/28706010
http://dx.doi.org/10.1634/theoncologist.2017-0142

Ejemplares similares